5-MeO-MPMI

5-MeO-MPMI
Systematic (IUPAC) name
(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole
Identifiers
CAS Number 143321-57-7 N
PubChem CID 9881324
ChemSpider 8057000 YesY
ChEMBL CHEMBL137485 YesY
Chemical data
Formula C15H19N2O
Molar mass 243.323 g/mol
 NYesY (what is this?)  (verify)

5-MeO-MPMI (also known as 5-Methoxy-N-methyl-(α,N-trimethylene)tryptamine) is a tryptamine derivative that is a psychedelic drug. It was first developed by the team led by JE Macor in 1992,[1] and subsequently investigated by the team led by David Nichols from Purdue University in the late 1990s. This compound produces psychedelic-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.[2]

See also

References

  1. Macor JE, Blake J, Fox CB, Johnson C, Koe BK, Lebel LA, Morrone JM, Ryan K, Schmidt AW, Schulz DW; et al. (1992). "Synthesis and serotonergic pharmacology of the enantiomers of 3-[(N-methylpyrrolidin-2-yl)methyl]-5-methoxy-1H-indole: discovery of stereogenic differentiation in the aminoethyl side chain of the neurotransmitter serotonin". Journal of Medicinal Chemistry 35 (23): 4503–4305. doi:10.1021/jm00101a032. PMID 1447752.
  2. Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE (1999). "Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain". Journal of Medicinal Chemistry 42 (20): 4257–4263. doi:10.1021/jm990325u. PMID 10514296.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.